A Comparison of Three Extrusion Systems (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Comparison of Three Extrusion Systems (Part II)
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.


Pharmaceutical Technology
Volume 35, Issue 6, pp. 56-61

References

1. A. Désiré et al., Pharm. Technol. 35 (1), 56–65 (2011).

2. C. Lustig-Gustafsson et al., Eur. J. Pharm. Sci. 8 (2), 147–152 (1999).

3. G. Tomer, F.Podczeck, and J.M. Newton, Int. J. Pharm. 217 (1–2), 237–248 (2001).

4. G. Tomer, F. Podczeck, and J.M. Newton, Int. J. Pharm. 231 (1), 248–257 (2002).

5. J.J. Sousa et al., Int. J. Pharm. 232 (1–2), 91–106 (2002).

6. J. Chatchawalsaisin, F. Podczeck, and J.M. Newton, Eur J Pharm Sci. 24 (1), 35–48 (2005).

7. D. Lutchman, C.M. Dangor, and D. Perumal, J. Microencapsul. 22 (6), 643–659 (2005).

8. F.O. Costa, A.A.C.C. Pais, and J.J.S., Int. J. Pharm. 270 (1–2), 9–19 (2004).

9. G.A. Hileman et al., Int. J. Pharm. 100 (1–3), 71–79 (1993).

10. L. Baert and G.R.B. Down, Int. J. Pharm. 107 (3), 219–222 (1994).

11. L. Alvarez et al., Eur. J. Pharm. Biopharm. 55 (3), 291–295 (2003).

12. R. Gandhi et al., Pharm. Technol. 29 (2). 68–86 (2005).

13. L. Rahman et al., STP Pharm. Sci. 1 (5), 294–299 (1991).

14. E. Nürnberg, and J. Wunderlich, Pharm. Technol. Eur. 11 (3), 30-34 (1999).

15. S. Galland, T. Ruiz, and M. Delalonde, Int. J. Pharm. 337 (1–2), 239–245 (2007).

16. S. Galland, T. Ruiz, and M. Delalonde, Powder Technol. 190 (1–2), 48–52 (2009).

17. J.F. Pinto and C.N. Abreu, Drug. Dev. Ind. Pharm. 32 (9), 1067–1078 (2006).

18. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 197–204 (1993).

19. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 205–216 (1993).

20. L. Hellén, J. Yliruusi, and E. Kristoffersson, Int. J. Pharm. 96 (1–3), 217–223 (1993).

21. A.M. Juppo et al., Eur. J. Pharm. Biopharm. 44 (2), 205–214 (1997).

22. V.R. Sinha et al., AAPSPharmSciTech, 8 (1), E1–E5 (2007).

23. S. Galland et al., Powder Technol. 157 (1–3), 156–162 (2005).

24. D. Sonaglio et al., Int. J. Pharm. 115 (1), 53–60 (1995).

25. E.I. Hamedelniel, J.Bajdik, and K.Pintye-Hódi, Chemical Engineering and Processing: Process Intensification 49 (1), 120–124 (2010).

26. A. Häring, K. Krejcova, and M. Rabiskova, Farm. Vestn. 54 (special issue), 437–438 (2003).

27. L. Baert et al., Int. J. Pharm. 86 (2–3), 187–192 (1992).

28. L. Baert et al., Int. J. Pharm. 99 (1), 7–12. (1993).

29. C. Schmidt, H. Lindner, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 44 (2), 169–176 (1997).

30. K. Thoma and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 401–411 (1998).

31. K. Thoma, and I. Ziegler, Drug Dev. Ind. Pharm. 24 (5), 413–422 (1998).

32. D. Sonaglio, B. Bataille, and M. Jacob, Pharm. Acta Helv. 72 (2), 69–74 (1997).

33. C. Schmidt, and P. Kleinebudde, Eur. J. Pharm. Biopharm. 45 (2), 173–179 (1998).

34. J.M. Newton, S.R. Chapman, and R.C. Rowe, Int. J. Pharm. 120 (1), 101–109 (1995).

35. D. Sonaglio et al., Pharmazie 52 (2), 129–134 (1997).

36. P. Costa and J.M. Sousa Lobo, Eur. J. Pharm. Sci. 13 (2), 123–133 (2001).

37. E. Jerwanska et al., Int. J. Pharm. 121 (1), 65–71 (1995).

38. P. Kleinebudde and H. Lindner, Int. J. Pharm. 94 (1–3), 49–58 (1993).

39. A.B. Bashaiwoldu, F. Podczeck and J.M. Newton, Eur. J. Pharm. Sci. 21 (2–3), 119–129 (2004).

40. B. Song, S.L. Rough, and D.I. Wilson, Int. J. Pharm. 332 (1–2), 38–44 (2007).

41. J.P. Perez and M. Rabiskova, Int. J. Pharm. 242 (1–2), 349–351 (2002).

42. J.J. Sousa et al., Int. J. Pharm. 144 (2), 159–169 (1996).

43. J. Berggren and G. Alderborn, Int. J. Pharm. 219 (1–2), 113–126 (2001).

44. P. Kleinebudde, Int. J. Pharm. 109 (3), 209–219 (1994).

45. P. Kleinebudde, Int. J. Pharm. 109 (3), 221–227 (1994).

46. B. Bataille, K. Ligarski, and M. Jacob, Pharm. Acta Helv. 65 (12), 334–337 (1990).

47. K. Ligarski et al., STP Pharma Sci. 1 (4), 256–261 (1991).

48. B. Bataille et al., Drug Dev. Ind. Pharm. 19 (6), 653–671 (1993).

49. K. Umprayn, P. Chitropas, and S. Amarekajorn, Drug Dev. Ind. Pharm. 25 (1), 45–61 (1999).

Citation: When referring to this article, please cite it as "Amelie Desire, Bruno Paillard, Joel Bougaret, Michel Baron, Guy Couarraze, "A Comparison of Three Extrusion Systems (Part II)," Pharmaceutical Technology 35 (6) 56-61(2011)."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here